97
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients

, , , , , & show all
Pages 615-617 | Received 29 Mar 2019, Accepted 15 Apr 2019, Published online: 12 May 2019

References

  • Eriksen J, Albert J, Blaxhult A, et al. Antiretroviral treatment for HIV infection: Swedish recommendations 2016. Infect Dis (Lond). 2017;49:1–34.
  • World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2016. Available from: http://www.who.int/hiv/pub/guidelines/arv2016/download/en/
  • Fontas E, van Leth F, Sabin CA, D:A:D Study Group, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056–1074.
  • Dave JA, Lambert EV, Badri M, et al. Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. J Acquir Immune Defic Syndr. 2011;57:284–289.
  • Sinxadi PZ, McIlleron HM, Dave JA, et al. Plasma efavirenz concentrations are associated with lipid and glucose concentrations. Medicine (Baltimore). 2016;95:e2385.
  • Gallant J, Seekins D, Hicks C, et al. A phase II, double-blind, placebo-control, dose-ranging study to assess the antiretroviral activity & safety of efavirenz (EFZ, sustiva, DMP266) in combination with open-label zidovudine (ZDV) w/lamivudine (3TC) at >48 weeks. [DMP266-005]. Intersci Conf Antimicrob Agents Chemother. 1998;24–27:38–441.
  • ENCORE1 Study Group, Carey D, Puls R, Amin J, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015;15:793–802.
  • Lanzafame M, Bonora S, Lattuada E, et al. Efavirenz dose reduction in HIV-infected patients. HIV Med. 2012;13:252–253.
  • Lanzafame M, Lattuada E, Cucchetto G, et al. Efavirenz dose reduction in HIV-infected patients: a long-term follow-up. AIDS. 2014;28:2789–2790.
  • Santos JR, Saumoy M, Curran A, et al. Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. J Int AIDS Soc. 2014;17(4):19550.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.